Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Circulation

• Publication date

  1999-11-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.100.19.1977PMID 10556224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.

  1999cited by this paper
• Rapid platelet-function assay: an automated and quantitative cartridge-based method.

  1999cited by this paper
• Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.

  1998cited by this paper
• Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.

  1998cited by this paper
• Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.

  1998cited by this paper
• Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.

  1997cited by this paper
• First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions.

  1997cited by this paper
• Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

  1997cited by this paper
• Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.

  1997cited by this paper
• Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry.

  1996cited by this paper
• Platelet size: measurement, physiology and vascular disease.

  1996cited by this paper
• Platelets from patients with diabetes mellitus have impaired ability to mediate vasodilation.

  1996cited by this paper
• Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease.

  1996cited by this paper
• Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.

  1995cited by this paper
• Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty.

  1995cited by this paper
• Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

  1994cited by this paper
• Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

  1994cited by this paper
• Randomized Trial of a GPIIb/IIIa Platelet Receptor Blocker in Refractory Unstable Angina

  1994cited by this paper
• Platelet abnormalities in diabetes mellitus.

  1993cited by this paper
• Mean platelet volume in diabetes mellitus.

  1993cited by this paper
• Platelet Abnormalities in Diabetes Mellitus

  1992cited by this paper
• Hypersensitivity to ADP of platelets from diabetic rats associated with enhanced fibrinogen binding

  1992cited by this paper
• Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agents a

  1991cited by this paper
• Evidence for abnormal platelet glycoprotein expression in diabetes mellitus

  1990cited by this paper
• NONENZYMATIC GLYCATI0N OF HUMAN BLOOD PLATELET PROTEINS

  1989cited by this paper
• Nonenzymatic glycation of human platelet membrane proteins in vitro and in vivo.

  1986cited by this paper

• Embedding a commitment to equitable global access into basic and early-phase translational research

  2025cites this paper
• Platelets in thrombosis and atherosclerosis: a double-edged sword.

  2024cites this paper
• Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches

  2022cites this paper
• Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases

  2021cites this paper
• Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel αIIbβ3 Receptor Antagonist

  2021cites this paper
• First Human Use of RUC‐4: A Nonactivating Second‐Generation Small‐Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point‐of‐Care Treatment of ST‐Segment–Elevation Myocardial Infarction

  2020cites this paper
• Point-of-Care Fibrinogen Testing in Pregnancy.

  2019cites this paper
• Point-of-Care Fibrinogen Testing in Pregnancy.

  2019cites this paper
• chieved Platelet Aggregation Inhibition fter Different Antiplatelet Regimens uring Percutaneous Coronary Intervention or ST-Segment Elevation Myocardial Infarction

  2016cites this paper
• Anticoagulant treatment in patients with diabetes

  2013cites this paper
• Platelet Cd Markers By Flow Cytometry In Normal Individuals And In Patients With Untreated Type 2 Diabetes Mellitus

  2013cites this paper
• and heparin administration Platelet function monitoring with the Sonoclot analyzer after in vitro tirofiban

  2013cites this paper
• 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention

  2013cites this paper
• 40 – Point-of-Care Hemostasis Testing

  2013cites this paper
• 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary

  2012cites this paper
• Resistance to antiplatelet treatment: The clinical relevance of platelet function assays

  2012cites this paper
• Glycoprotein IIb/IIIa Antagonists in Acute Ischaemic Stroke

  2012cites this paper
• Abciximab

  2012cites this paper
• Stenting in Acute STEMI Intervention.

  2012cites this paper
• Effect of tailored antiplatelet therapy on periprocedural myonecrosis in patients with diabetes mellitus (from the DM-Verify Now Trial).

  2012cites this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cites this paper
• GPIIb/IIIa inhibitors and aspirin Desmopressin antagonizes the in vitro platelet dysfunction induced by

  2011cites this paper
• ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions

  2011cites this paper
• Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions

  2011cites this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cites this paper
• A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice

  2010cites this paper
• Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence.

  2008cites this paper
• Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study

  2008cites this paper
• Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes

  2008cites this paper
• Pharmacologic Inhibition of Platelet Function

  2008cites this paper
• Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions.

  2008cites this paper
• CHAPTER 38 – Diabetes Mellitus

  2007cites this paper
• Chapter 41 – Point-of-Care Testing for Hemostatic Disorders

  2007cites this paper
• Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention.

  2007cites this paper
• Platelet function monitoring with the Sonoclot analyzer after in vitro tirofiban and heparin administration.

  2006cites this paper
• Transmutation of metal at low energy in a confined plasma in water

  2006cites this paper
• Coagulation monitoring.

  2006cites this paper
• Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention.

  2006cites this paper
• Antiplatelet agents and perioperative bleeding

  2006cites this paper
• Evidence Based Coagulation Monitors: Heparin Monitoring, Thromboelastography, and Platelet Function

  2005cites this paper
• Aus dem Institut für Pharmakologie und Klinische Pharmakologie der Heinrich-Heine-Universität Düsseldorf

  2005cites this paper
• Platelet function tests and flow cytometry to monitor antiplatelet therapy.

  2005cites this paper
• Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network.

  2005cites this paper
• Leczenie przeciwpłytkowe w ostrych zespołach wieńcowych Antiplatelet treatment in acute coronary syndromes

  2005cites this paper
• Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting.

  2005cites this paper
• Platelet Function Studies

  2005cites this paper
• Non-ST-elevation acute coronary syndromes management : a fresh look at glycoprotein IIb/IIIa inhibitors

  2005cites this paper
• Diabetes and Percutaneous Interventional Therapy

  2005cites this paper
• Platelet Function Tests and Flow Cytometry to Monitor Antiplatelet Therapy

  2005cites this paper
• Diabetes Mellitus and Heart Disease

  2005cites this paper
• Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes.

  2004influential citation
• Platelet-active drugs: the relationships among dose, effectiveness, and side effects.

  2004cites this paper
• Abciximab Pharmacodynamic Model with Neural Networks used to Integrate Sources of Patient Variability

  2004cites this paper
• Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.

  2004cites this paper
• Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cites this paper
• Point‐of‐care testing shows clinically relevant variation in the degree of inhibition of platelets by standard‐dose abciximab therapy during percutaneous coronary intervention

  2004cites this paper
• Platelet-active drugs : the relationships among dose, effectiveness, and side effects.

  2004cites this paper
• Admission troponin T, advanced age and male gender identify patients with improved myocardial tissue perfusion after abciximab administration for ST-segment elevation myocardial infarction

  2004influential citation
• Evaluation of Platelet Count and Function in Patients Administered Tirofiban or Eptifibatide Undergoing Percutaneous Coronary Intervention

  2004cites this paper
• Bedside Platelet Monitoring

  2004cites this paper
• The Role of Glycoprotein IIb/IIIa-Receptor Antagonists in Diabetics

  2003cites this paper
• Glycoprotein IIb/IIIa Antagonists

  2003cites this paper
• DESMOPRESSIN AND PLATELETS ANTAGONIZE THE IN VITRO PLATELET DYSFUNCTION INDUCED BY GPIIb / IIIa INHIBITORS AND ASPIRIN 1

  2003cites this paper
• Hemostatic Abnormalities in Diabetes

  2003cites this paper
• Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.

  2003cites this paper
• Abciximab During Percutaneous Coronary Intervention

  2003cites this paper
• Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial.

  2003cites this paper
• Platelet abnormalities in diabetes mellitus

  2003cites this paper
• Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban

  2003cites this paper
• Platelets and anti-platelet therapy.

  2003cites this paper
• Sind GPIIb/IIIa-Rezeptor-Antagonisten bei Diabetikern sinnvoll?

  2003cites this paper
• Platelet Monitoring and Interaction of Glycoprotein IIb/IIIa Antagonists with Other Antiplatelet Agents

  2003cites this paper
• Unstable Angina Trials

  2003cites this paper
• GPIIb/IIIa Antagonists and Other Anti-Integrins

  2003cites this paper
• Antithrombozytärer Effekt von Abciximab, Tirofiban und Eptifibatide bei Patienten nach koronarer Stentimplantation

  2003cites this paper
• Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.

  2003cites this paper
• Simultaneous Modeling of Abciximab Plasma Concentrations and ex Vivo Pharmacodynamics in Patients Undergoing Coronary Angioplasty

  2003cites this paper
• Blood histamine is associated with coronary artery disease, cardiac events and severity of inflammation and atherosclerosis

  2002cites this paper
• Glycoprotein IIb/IIIa antagonists - from bench to practice

  2002cites this paper
• Impact of Different Platelet Glycoprotein IIb/IIIa Receptor Inhibitors Among Diabetic Patients Undergoing Percutaneous Coronary Intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-Year Follow-Up

  2002cites this paper
• Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100.

  2002cites this paper
• Inhibition of Platelet‐Collagen Interaction An In Vivo Action of Insulin Abolished by Insulin Resistance in Obesity

  2002cites this paper
• Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes: The COMPARE Trial

  2002cites this paper
• Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable.

  2002cites this paper
• The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.

  2002cites this paper
• Reduced inhibition by abciximab in platelets with the PlA2 polymorphism.

  2002cites this paper
• Clinical Pharmacokinetics of Tirofiban, a Nonpeptide Glycoprotein IIb/IIIa Receptor Antagonist

  2002cites this paper
• Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes.

  2002cites this paper
• Pharmaceutical thrombosis prevention in cardiovascular disease

  2002cites this paper
• Monitoring of platelet function in the setting of glycoprotein IIb/IIIa inhibitor therapy.

  2002cites this paper
• Effects of Different Thrombolytic Treatment Regimen with Abciximab and Tirofiban on Platelet Aggregation and Platelet-Leukocyte Interactions: A Subgroup Analysis from the GUSTO V and FASTER Trials

  2002cites this paper
• Is there a bleeding problem with platelet-active drugs?

  2002cites this paper
• The laboratory diagnosis of platelet disorders.

  2002cites this paper
• „Rescue“-Indikation für Glykoprotein-IIb/IIIa-Rezeptor-Inhibition im Rahmen perkutaner Koronarintervention?

  2002cites this paper
• Monitoring Glycoprotein IIb-IIIa Antagonists in Patients with Coronary Artery Disease/Monitoring von Glykoprotein IIb-IIIa-Antagonisten bei Patienten mit koronarer Herzerkrankung

  2002cites this paper
• The Laboratory Diagnosis of Platelet Disorders An Algorithmic Approach

  2002cites this paper
• Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction.

  2001cites this paper
• Obesity Inhibition of Platelet-Collagen Interaction : An In Vivo Action of Insulin Abolished

  2001cites this paper
• Will diabetes save the platelet blockers?

  2001cites this paper
• Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.

  2001cites this paper